ABC Arbitrage SA Buys 74,504 Shares of Smith & Nephew SNATS, Inc. $SNN

ABC Arbitrage SA raised its stake in Smith & Nephew SNATS, Inc. (NYSE:SNN) by 10.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 757,956 shares of the medical equipment provider’s stock after purchasing an additional 74,504 shares during the quarter. Smith & Nephew SNATS accounts for about 2.3% of ABC Arbitrage SA’s portfolio, making the stock its 14th biggest position. ABC Arbitrage SA’s holdings in Smith & Nephew SNATS were worth $24,869,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of SNN. Versant Capital Management Inc grew its holdings in Smith & Nephew SNATS by 5.0% during the third quarter. Versant Capital Management Inc now owns 8,912 shares of the medical equipment provider’s stock worth $323,000 after buying an additional 423 shares in the last quarter. Vise Technologies Inc. lifted its position in shares of Smith & Nephew SNATS by 4.7% during the 3rd quarter. Vise Technologies Inc. now owns 9,642 shares of the medical equipment provider’s stock worth $350,000 after buying an additional 437 shares in the last quarter. Quadrant Capital Group LLC boosted its position in Smith & Nephew SNATS by 3.6% in the third quarter. Quadrant Capital Group LLC now owns 12,757 shares of the medical equipment provider’s stock worth $463,000 after purchasing an additional 440 shares during the last quarter. First Trust Advisors LP boosted its holdings in shares of Smith & Nephew SNATS by 4.6% in the 3rd quarter. First Trust Advisors LP now owns 10,532 shares of the medical equipment provider’s stock worth $382,000 after buying an additional 459 shares during the last quarter. Finally, Park Avenue Securities LLC boosted its stake in Smith & Nephew SNATS by 5.7% in the fourth quarter. Park Avenue Securities LLC now owns 9,574 shares of the medical equipment provider’s stock valued at $314,000 after acquiring an additional 515 shares during the last quarter. Hedge funds and other institutional investors own 25.64% of the company’s stock.

Analyst Upgrades and Downgrades

SNN has been the topic of a number of research reports. Wall Street Zen cut shares of Smith & Nephew SNATS from a “strong-buy” rating to a “buy” rating in a report on Saturday. Canaccord Genuity Group decreased their target price on Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a research report on Monday. Weiss Ratings reiterated a “hold (c+)” rating on shares of Smith & Nephew SNATS in a research note on Monday, April 20th. Finally, Sanford C. Bernstein set a $31.85 price objective on Smith & Nephew SNATS in a report on Monday. One equities research analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $30.93.

Smith & Nephew SNATS Price Performance

Shares of Smith & Nephew SNATS stock opened at $29.12 on Tuesday. Smith & Nephew SNATS, Inc. has a 12 month low of $27.97 and a 12 month high of $38.79. The business’s 50-day moving average price is $32.77 and its 200-day moving average price is $33.55. The company has a current ratio of 2.57, a quick ratio of 1.25 and a debt-to-equity ratio of 0.60.

Smith & Nephew SNATS (NYSE:SNN) last released its quarterly earnings data on Tuesday, February 17th. The medical equipment provider reported $29.55 EPS for the quarter. The company had revenue of $1.60 billion during the quarter. Analysts expect that Smith & Nephew SNATS, Inc. will post 2.29 EPS for the current year.

Smith & Nephew SNATS Announces Dividend

The business also recently announced a dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Friday, March 27th will be paid a dividend of $0.482 per share. The ex-dividend date of this dividend is Friday, March 27th. This represents a dividend yield of 304.0%.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.